Implant placement guide

Description

FIG. 1 is a perspective view of our design for an implant placement guide;

FIG. 2 is a first side view of the design for the implant placement guide of FIG. 1;

FIG. 3 is a second side view of the design for the implant placement guide of FIG. 1;

FIG. 4 is a front view of the design for the implant placement guide of FIG. 1;

FIG. 5 is a back view of the design for the implant placement guide of FIG. 1;

FIG. 6 is a top view for the design for the implant placement guide of FIG. 1; and,

FIG. 7 is a bottom view for the design of the implant placement guide of FIG. 1.

Claims

CLAIM The ornamental design for an implant placement guide, as shown and described.

---

Inventors:	Smith; Jay S. (Wellesley Hills, MA), Cole; Michael R. (Stratham, NH), Whitson; Amy K. (Columbus, OH)
Applicant:	Name City State Country Type Intarcia Therapeutics, Inc. Boston MA US
Assignee:	Intarcia Therapeutics, Inc. (Boston, MA)
Appl. No.:	D/566,823
Filed:	June 2, 2016

---

Current U.S. Class:	D24/140; D24/133
Current International Class:	2402
Field of Search:	;D24/140,231,133,146,147,155,169,141

---

References Cited [Referenced By]

---

U.S. Patent Documents

1655158	January 1928	Muir
2110208	March 1938	Eggert
2168437	August 1939	Buercklin
2531724	November 1950	Cevasco
2643653	June 1953	Heidrich
D179537	January 1957	Floyd
3016895	January 1962	Sein
3025991	March 1962	Gillon
3122162	February 1964	Sands
35232906	August 1970	Vrancken et al.
3538916	November 1970	Groff et al.
3620216	November 1971	Szymanski
3625214	December 1971	Higuchi
3632768	January 1972	Bergy et al.
3669104	June 1972	Wyatt et al.
3691090	September 1972	Kitajima et al.
D226915	May 1973	Huggins
3732865	May 1973	Higuchi et al.
3737337	June 1973	Sonnoring et al.
3766915	October 1973	Rychlik
3773919	November 1973	Boswell et al.
3797492	March 1974	Place
3869549	March 1975	Geller
3891570	June 1975	Fukushima et al.
D236035	July 1975	Ciencewicki
3960757	June 1976	Morishita et al.
3987790	October 1976	Eckenhoff et al.
3995631	December 1976	Higuchi et al.
3995632	December 1976	Nakano et al.
4008719	February 1977	Theeuwes et al.
4034756	July 1977	Higuchi et al.
4078060	March 1978	Benson et al.
4105030	August 1978	Kercso
4111201	September 1978	Theeuwes
4111202	September 1978	Theeuwes
4111203	September 1978	Theeuwes
4203439	May 1980	Theeuwes
4211771	July 1980	Witkowski et al.
4221862	September 1980	Naito et al.
4223674	September 1980	Fluent et al.
4243030	January 1981	Lynch et al.
D258837	April 1981	Spranger
D259458	June 1981	Fuller
4305927	December 1981	Theeuwes et al.
4310516	January 1982	Chang et al.
4340054	July 1982	Michaels
4350271	September 1982	Eckenhoff
4373527	February 1983	Fischell
4376118	March 1983	Daher
4384975	May 1983	Fong
4389330	June 1983	Tice et al.
D271990	December 1983	Lyne
4439196	March 1984	Higuchi
4444498	April 1984	Heinemann
4451253	May 1984	Harman
4455143	June 1984	Theeuwes et al.
4455145	June 1984	Theeuwes
4474572	October 1984	McNaughton et al.
4530840	July 1985	Tice et al.
4552561	November 1985	Eckenhoff et al.
4588614	May 1986	Lauchenauer
4594108	June 1986	Greminger, Jr. et al.
4597753	July 1986	Turley
4609374	September 1986	Ayer
4639244	January 1987	Rizk et al.
4655462	April 1987	Balsells
4673405	June 1987	Guittard et al.
4675184	June 1987	Hasegawa et al.
4695623	September 1987	Stabinsky
4727138	February 1988	Goeddel et al.
4734284	March 1988	Terada et al.
4737437	April 1988	Gutseil, Jr. et al.
4743449	May 1988	Yoshida et al.
4753651	June 1988	Eckenhoff
4762791	August 1988	Goeddel et al.
4765989	August 1988	Wong et al.
4783337	November 1988	Wong et al.
4818517	April 1989	Kwee et al.
4820267	April 1989	Harman
4820638	April 1989	Swetly et al.
4826144	May 1989	Balsells
4830344	May 1989	Balsells
4834708	May 1989	Pillari
4840896	June 1989	Reddy et al.
4845196	July 1989	Cowling
4847079	July 1989	Kwan
4851228	July 1989	Zentner et al.
4865845	September 1989	Eckenhoff et al.
4871094	October 1989	Gall et al.
4873080	October 1989	Brickl et al.
4874388	October 1989	Wong et al.
4876781	October 1989	Balsells
4882166	November 1989	Graham et al.
4885166	December 1989	Meyer et al.
4886668	December 1989	Haslam et al.
4892778	January 1990	Theeuwes et al.
4893795	January 1990	Balsells
4897471	January 1990	Stabinsky
4907788	March 1990	Balsells
4915366	April 1990	Balsells
4915949	April 1990	Wong et al.
4915954	April 1990	Ayer et al.
4917887	April 1990	Hauptmann et al.
4917895	April 1990	Lee et al.
4923805	May 1990	Reddy et al.
4927687	May 1990	Nuwayser
4929554	May 1990	Goeddel et al.
4931285	June 1990	Edgren et al.
4934666	June 1990	Balsells
4940465	July 1990	Theeuwes et al.
4940588	July 1990	Sparks et al.
4952402	August 1990	Sparks et al.
4957119	September 1990	de Nijs
4961253	October 1990	Balsells
4964204	October 1990	Balsells
4969884	November 1990	Yum
4974821	December 1990	Balsells
4976966	December 1990	Theeuwes et al.
4994028	February 1991	Leonard et al.
5004689	April 1991	Fiers et al.
5006346	April 1991	Theeuwes et al.
5019382	May 1991	Cummins, Jr.
5019400	May 1991	Gombotz et al.
5023088	June 1991	Wong et al.
5024842	June 1991	Edgren et al.
5030216	July 1991	Theeuwes et al.
5034229	July 1991	Magruder et al.
5053014	October 1991	Van Heugten
5057318	October 1991	Magruder et al.
5059423	October 1991	Magruder et al.
5066436	November 1991	Komen et al.
5071642	December 1991	Lahr et al.
5072070	December 1991	Balsells
5079388	January 1992	Balsells
5090962	February 1992	Landry et al.
5091188	February 1992	Haynes
5108078	April 1992	Balsells
5110596	May 1992	Magruder et al.
5112614	May 1992	Magruder et al.
5113938	May 1992	Clayton
5117066	May 1992	Balsells
D326718	June 1992	Maxwell
5118666	June 1992	Habener
5120306	June 1992	Gosselin
5120712	June 1992	Habener
5120832	June 1992	Goeddel et al.
5122128	June 1992	Cardinal et al.
5122377	June 1992	Miller
5126142	June 1992	Ayer et al.
5126147	June 1992	Silvestri et al.
5134244	July 1992	Balsells
5137727	August 1992	Eckenhoff
D329278	September 1992	Gallup
5147295	September 1992	Stewart
5151093	September 1992	Theeuwes et al.
5160122	November 1992	Balsells
5160743	November 1992	Edgren et al.
5161806	November 1992	Balsells
5180591	January 1993	Margruder et al.
5190765	March 1993	Jao et al.
5192273	March 1993	Bierman
5203849	April 1993	Balsells
5204108	April 1993	Illum
5207752	May 1993	Sorenson et al.
5209746	May 1993	Balaban et al.
5213809	May 1993	Wright et al.
5213810	May 1993	Steber
5219572	June 1993	Sivaramakrishnan
5221278	June 1993	Linkwitz et al.
5223265	June 1993	Wong
5225205	July 1993	Orsolini
5231176	July 1993	Goeddel et al.
5234424	August 1993	Yum et al.
5234692	August 1993	Magruder et al.
5234693	August 1993	Magruder et al.
5234695	August 1993	Hobbs et al.
5250026	October 1993	Ehrlich et al.
5252338	October 1993	Jao et al.
5260069	November 1993	Chen
D342855	January 1994	Butler, II
5276926	January 1994	Lopez
5278151	January 1994	Korb et al.
5279544	January 1994	Gross et al.
5279554	January 1994	Turley
5279555	January 1994	Lifshey
5279608	January 1994	Cherif Cheikh
5284655	February 1994	Bogdansky et al.
5288501	February 1994	Nurnberg et al.
5288502	February 1994	Mcginity et al.
5290271	March 1994	Jemberg
5300079	April 1994	Niezink et al.
5300302	April 1994	Tachon et al.
5308348	May 1994	Balaban et al.
5312335	May 1994	McKinnon et al.
5312389	May 1994	Theeuwes et al.
5312390	May 1994	Wong
5318558	June 1994	Linkwitz et al.
5318780	June 1994	Viegas et al.
5320616	June 1994	Magndu et al.
5324280	June 1994	Wong et al.
5336057	August 1994	Fukuda et al.
5336505	August 1994	Ng et al.
5348544	September 1994	Sweeney et al.
5352662	October 1994	Brooks et al.
5368588	November 1994	Bettinger
5368863	November 1994	Eckenhoff et al.
5371089	December 1994	Rattan
5374620	December 1994	Clark et al.
5385738	January 1995	Yamahira et al.
5385887	January 1995	Yim et al.
5395319	March 1995	Hirsch et al.
5407609	April 1995	Tice et al.
D358644	May 1995	Park
5411951	May 1995	Mitchell
5413572	May 1995	Wong
5413672	May 1995	Hirotsuji et al.
5424286	June 1995	Eng
5428024	June 1995	Chu et al.
5429602	July 1995	Hauser
5439688	August 1995	Orsolini et al.
5443459	August 1995	Wong et al.
5445829	August 1995	Paradissis et al.
5456679	October 1995	Balaban et al.
5458888	October 1995	Chen
5464929	November 1995	Bezwada et al.
5472708	December 1995	Chen
5473564	December 1995	Wantier et al.
5484403	January 1996	Yoakum et al.
5486365	January 1996	Takado et al.
5498255	March 1996	Wong et al.
5511355	April 1996	Dingler
5512293	April 1996	Landrau et al.
5512549	April 1996	Chen et al.
5514110	May 1996	Teh
5529914	June 1996	Hubbell et al.
5531736	July 1996	Wong et al.
5540665	July 1996	Mercado et al.
5540912	July 1996	Roorda et al.
5541172	July 1996	Labrie et al.
5542682	August 1996	Goldstein et al.
5543156	August 1996	Roorda et al.
5545618	August 1996	Buckley et al.
5556642	September 1996	Kobayashi et al.
5557318	September 1996	Gabriel
5558637	September 1996	Allonen et al.
5569289	October 1996	Yoon
5571525	November 1996	Roorda et al.
5574008	November 1996	Johnson et al.
5574137	November 1996	Gray et al.
5580578	December 1996	Oshlack et al.
5589167	December 1996	Cleland et al.
5595751	January 1997	Bezwada
5595759	January 1997	Wright et al.
5597579	January 1997	Bezwada et al.
5602010	February 1997	Hauptmann et al.
5605688	February 1997	Himmler et al.
5607687	March 1997	Bezwada et al.
5609885	March 1997	Rivera et al.
5613954	March 1997	Nelson et al.
5614221	March 1997	Fjellstrom
5614492	March 1997	Habener
5618552	April 1997	Bezwada et al.
5620698	April 1997	Bezwada et al.
5620705	April 1997	Dong et al.
5630796	May 1997	Bellhouse et al.
5633011	May 1997	Dong et al.
5635213	June 1997	Nystrom et al.
5639477	June 1997	Maruyama et al.
5639640	June 1997	Reddy et al.
5645850	July 1997	Bezwada et al.
5648088	July 1997	Bezwada et al.
5650173	July 1997	Ramstack et al.
5654008	August 1997	Herbert et al.
5654010	August 1997	Johnson et al.
5656297	August 1997	Bernstein et al.
5656299	August 1997	Kino et al.
5658593	August 1997	Orly et al.
5660847	August 1997	Magruder et al.
5660858	August 1997	Parikh et al.
5660861	August 1997	Jao et al.
5667803	September 1997	Johnson et al.
5668170	September 1997	Gyory
5672549	September 1997	Minami et al.
5676942	October 1997	Testa et al.
5686097	November 1997	Taskovich et al.
5688801	November 1997	Mesens et al.
5690925	November 1997	Gray et al.
5690952	November 1997	Magruder et al.
5695463	December 1997	Cherif-Cheikh
5697113	December 1997	Shatz
5697914	December 1997	Brimhall
5698213	December 1997	Jamiolkowski et al.
5700486	December 1997	Canal et al.
5700583	December 1997	Jamiolkowski et al.
5703200	December 1997	Bezwada et al.
5707644	January 1998	Illum
5711967	January 1998	Juch
5713847	February 1998	Howard, III et al.
5718922	February 1998	Herrero-Vanrell
5725497	March 1998	Woodruff et al.
5728088	March 1998	Margruder et al.
5728396	March 1998	Peery et al.
5733572	March 1998	Unger et al.
5736159	April 1998	Chen et al.
5738845	April 1998	Imakawa
5747058	May 1998	Tipton et al.
5756450	May 1998	Lorenz et al.
5767251	June 1998	Reddy et al.
5770231	June 1998	Mesens et al.
5782396	July 1998	Mastri et al.
5792477	August 1998	Rickey et al.
5795591	August 1998	Lee et al.
5795779	August 1998	McCormick et al.
5807876	September 1998	Armistead et al.
5810769	September 1998	Schlegel et al.
5814323	September 1998	Lyle
D399821	October 1998	Tyneski
5817129	October 1998	Labrecque et al.
5827297	October 1998	Boudjema
5830501	November 1998	Dong et al.
5836935	November 1998	Ashton et al.
5843891	December 1998	Sherman
5844017	December 1998	Jamiolkowslci et al.
5851451	December 1998	Takechi et al.
5858746	January 1999	Hubbell et al.
5859150	January 1999	Jamiolkowski et al.
5861166	January 1999	Eckenhoff
5871770	February 1999	Margruder et al.
5871778	February 1999	Kino et al.
5874388	February 1999	Hsu
5876746	March 1999	Jona et al.
5882676	March 1999	Lee et al.
D408917	April 1999	Hacker
5904935	May 1999	Eckenhoff et al.
5906599	May 1999	Kaldany
5906816	May 1999	Soos et al.
5906830	May 1999	Farinas et al.
5908621	June 1999	Glue et al.
5916598	June 1999	Rickey et al.
5922253	July 1999	Herbert et al.
5928666	July 1999	Farinas et al.
5932547	August 1999	Stevenson et al.
5938654	August 1999	Wong et al.
5939286	August 1999	Johnson et al.
5942223	August 1999	Bazer et al.
5942253	August 1999	Gombotz et al.
5945126	August 1999	Thanoo et al.
5948430	September 1999	Zerbe et al.
5951521	September 1999	Mastrototaro et al.
5958909	September 1999	Habener
D415073	October 1999	Meehan
5962023	October 1999	Jamiolkowski et al.
5965168	October 1999	Mesens et al.
5972370	October 1999	Eckenhoff et al.
5972373	October 1999	Yajima et al.
5976109	November 1999	Heruth
5980945	November 1999	Ruiz
5981719	November 1999	Woiszwillo et al.
5984890	November 1999	Gast et al.
5985305	November 1999	Peery et al.
5989463	November 1999	Tracy et al.
5997527	December 1999	Gumucio et al.
5997902	December 1999	Maruyama et al.
6007805	December 1999	Foster et al.
6017545	January 2000	Modi
6022561	February 2000	Carlsson et al.
6023802	February 2000	King
6029361	February 2000	Newman
6053927	April 2000	Hamas
6056718	May 2000	Funderburk et al.
6060450	May 2000	Soos et al.
6069133	May 2000	Carlo et al.
6074377	June 2000	Sanfilippo, II
6074660	June 2000	Jamiolkowski et al.
6074673	June 2000	Guillen
6100346	August 2000	Jamiolkowski et al.
6110503	August 2000	Rickey et al.
D430671	September 2000	Shute
6113938	September 2000	Chen et al.
6113947	September 2000	Cleland et al.
6120787	September 2000	Gustafsson et al.
6124261	September 2000	Stevenson et al.
6124281	September 2000	Lewis et al.
6127520	October 2000	Ueda et al.
6129761	October 2000	Hubbell
6130200	October 2000	Brodbeck et al.
6132420	October 2000	Dionne et al.
6133249	October 2000	Hills
6133429	October 2000	Davis et al.
6146139	November 2000	Harrison, III
6147168	November 2000	Jamiolkowski et al.
6156331	December 2000	Peery et al.
6172046	January 2001	Albrecht
6174547	January 2001	Dong et al.
6177096	January 2001	Zerbe et al.
6183461	February 2001	Matsuura et al.
6187095	February 2001	Labrecque et al.
6190350	February 2001	Davis et al.
6190700	February 2001	Okada et al.
6190702	February 2001	Takada et al.
6191102	February 2001	DiMarchi et al.
6204022	March 2001	Johnson et al.
6217393	April 2001	Pellet et al.
6217906	April 2001	Gumucio et al.
6217908	April 2001	Mathiowitz et al.
6218431	April 2001	Schoen et al.
6224894	May 2001	Jamiolkowski et al.
6235712	May 2001	Stevenson et al.
6245349	June 2001	Yiv et al.
6245357	June 2001	Edgren et al.
6248112	June 2001	Gambale et al.
6251435	June 2001	Jamiolkowski et al.
D445975	July 2001	Stratford
6258377	July 2001	New et al.
6261584	July 2001	Peery et al.
6268343	July 2001	Knudsen et al.
6270700	August 2001	Ignatious
6270787	August 2001	Ayer
6277413	August 2001	Sankaram
6283949	September 2001	Roorda
6284264	September 2001	Zerbe et al.
6284727	September 2001	Kim et al.
6287295	September 2001	Chen et al.
6284725	December 2001	Coolidge et al.
6329336	December 2001	Bridon et al.
6331311	December 2001	Brodbeck et al.
6372218	April 2002	Cummins, Jr.
6372256	April 2002	Jamiolkowski et al.
6375978	April 2002	Kleiner et al.
D456776	May 2002	Lindekugel
6395282	May 2002	Kende et al.
6395292	May 2002	Peery et al.
6402716	June 2002	Ryoo et al.
6403655	June 2002	Bezwada et al.
6419952	July 2002	Wong et al.
6428517	August 2002	Hochman et al.
6433144	August 2002	Morris et al.
6436091	August 2002	Harper et al.
6447522	September 2002	Gambale et al.
6451974	September 2002	Hansen
6458385	October 2002	Jamiolkowski et al.
6458387	October 2002	Scott et al.
6458924	October 2002	Knudsen et al.
6461605	October 2002	Cutler et al.
6464688	October 2002	Harper et al.
6468961	October 2002	Brodbeck et al.
6471688	October 2002	Harper et al.
6472512	October 2002	LaFleur et al.
6478768	November 2002	Kneer
6485706	November 2002	McCoy et al.
6495164	December 2002	Ramstack et al.
6506724	January 2003	Hiles et al.
6508808	January 2003	Carr et al.
6514500	February 2003	Bridon et al.
6514517	February 2003	Jamilolkowski et al.
6524305	February 2003	Peterson et al.
6528093	March 2003	Kamei et al.
6528486	March 2003	Larsen et al.
D472896	April 2003	Peiker
6541021	April 2003	Johnson et al.
6544239	April 2003	Kinsey et al.
6544252	April 2003	Theeuwes et al.
6547250	April 2003	Noble
6551613	April 2003	Dong et al.
6569420	May 2003	Chen et al.
6572890	June 2003	Faour et al.
6579851	June 2003	Goeke et al.
6589157	July 2003	Fontayne et al.
6592508	July 2003	Ravins et al.
6592887	July 2003	Zerbe et al.
6593295	July 2003	Bridon et al.
6607529	August 2003	Jones et al.
6626863	September 2003	Berler
6635268	October 2003	Peery et al.
6645192	November 2003	Kenison et al.
6667061	December 2003	Rarnstack et al.
6670368	December 2003	Breault et al.
6673767	January 2004	Brodbeck et al.
6682522	January 2004	Carr et al.
6703225	March 2004	Kojima et al.
6703359	March 2004	Young et al.
6706689	March 2004	Coolidge et al.
6709671	March 2004	Zerbe et al.
6720407	April 2004	Hughes et al.
6730328	May 2004	Maskiwicz et al.
6767887	July 2004	Hoffmann et al.
6821949	November 2004	Bridon et al.
6833256	December 2004	Pontzer et al.
6835194	December 2004	Johnson et al.
6840931	January 2005	Peterson et al.
6849708	February 2005	Habener
6849714	February 2005	Bridon et al.
6858576	February 2005	Young et al.
6872700	March 2005	Young et al.
6875748	April 2005	Manthorpe et al.
6887470	May 2005	Bridon et al.
6887849	May 2005	Bridon et al.
6899887	May 2005	Ayer
6899898	May 2005	Albayrak
6902744	June 2005	Kolterman et al.
6903186	June 2005	Dong
6913767	July 2005	Cleland et al.
6923800	August 2005	Chen et al.
6924264	August 2005	Prickett et al.
6939556	September 2005	Lautenbach
6956026	October 2005	Beeley et al.
6960192	November 2005	Flaherty et al.
6969702	November 2005	Bertilsson et al.
6976981	December 2005	Ayer
6989366	January 2006	Beeley et al.
6992065	January 2006	Okumu
6997922	February 2006	Theeuwes et al.
7008439	March 2006	Janzen et al.
7014636	March 2006	Gilbert
7022674	April 2006	DeFelippis et al.
7041646	May 2006	Pan et al.
7074423	July 2006	Fereira et al.
7084243	August 2006	Glaesner et al.
7101567	September 2006	Sano et al.
7101843	September 2006	Glaesner et al.
7112335	September 2006	Lautenbach
7115569	October 2006	Beeley et al.
7138375	November 2006	Beeley et al.
7138486	November 2006	Habener et al.
7141547	November 2006	Rosen et al.
7144863	December 2006	DeFelippis et al.
7153825	December 2006	Young
7157555	January 2007	Beeley et al.
7163688	January 2007	Peery et al.
7163697	January 2007	Hanes et al.
7199217	April 2007	DiMarchi et al.
7205409	April 2007	Pei et al.
7207982	April 2007	Dionne et al.
7214206	May 2007	Rue et al.
7241457	July 2007	Chen et al.
7258869	August 2007	Berry et al.
D555589	November 2007	Hussaini
7297761	November 2007	Beeley et al.
7316680	January 2008	Gilbert
7393827	July 2008	Nadler
7407499	August 2008	Trautman
7442682	October 2008	Kitaura et al.
7456254	November 2008	Wright et al.
7459432	December 2008	Cowley et al.
7521423	April 2009	Young et al.
7563871	July 2009	Wright et al.
7589169	September 2009	Bolotin
7604647	October 2009	Chen
7612176	November 2009	Wright et al.
7632256	December 2009	Mosler et al.
7635463	December 2009	Bolotin et al.
D608447	January 2010	Meyer
7655254	February 2010	Dennis et al.
7655257	February 2010	Peery et al.
7666835	February 2010	Bloom et al.
7682356	March 2010	Alessi et al.
7727519	June 2010	Moran
7731947	June 2010	Eliaz et al.
7736665	June 2010	Patel et al.
7741269	June 2010	Young et al.
7766924	August 2010	Bombard et al.
7790140	September 2010	Bolotin
7825091	November 2010	Bloom et al.
7829109	November 2010	Chen et al.
7833543	November 2010	Gibson et al.
7879028	February 2011	Alessi et al.
7879794	April 2011	Berry et al.
7919109	April 2011	Berry et al.
D638478	May 2011	Block
7928065	June 2011	Rohloff et al.
7964183	June 2011	Eliaz et al.
8039432	October 2011	Bridon et al.
7959938	November 2011	Lautenbach et al.
8048438	November 2011	Berry et al.
8052996	November 2011	Lautenbach et al.
8058233	November 2011	Cowley et al.
8101576	January 2012	Bloom
8114430	February 2012	Rohloff et al.
8114437	February 2012	Rohloff et al.
8158150	April 2012	Lautenbach et al.
8173150	May 2012	Berry et al.
8202836	June 2012	Moore et al.
8206745	June 2012	Rohloff et al.
8211467	July 2012	Rohloff et al.
8217001	July 2012	Cowley et al.
8231859	July 2012	Bolotin et al.
8251946	August 2012	Bardy
8257682	September 2012	Bolotin et al.
8257691	September 2012	Eliaz et al.
8262667	September 2012	Silver et al.
8263545	September 2012	Bloom
8263736	September 2012	Berry
8268341	September 2012	Berry
8273365	September 2012	Lautenbach et al.
8273713	September 2012	Pittner et al.
D669589	October 2012	Delaey
8277776	October 2012	Boictin et al.
8278267	October 2012	Weyer et al.
8288338	October 2012	Alessi et al.
8298561	October 2012	Alessi et al.
8299025	October 2012	Alessi et al.
8343140	January 2013	Alessi et al.
8367095	February 2013	Lautenbach et al.
8372424	February 2013	Berry et al.
D678889	March 2013	Chiu
8398967	March 2013	Eliaz et al.
8440226	May 2013	Rohloff et al.
8454552	June 2013	Bardy
8460694	June 2013	Rohloff et al.
8470353	June 2013	Lautenbach et al.
8556861	October 2013	Tsals
8722037	May 2014	Veenstra et al.
8747412	June 2014	Bae et al.
8801700	August 2014	Alessi et al.
8815802	August 2014	Kalthoff et al.
8845726	September 2014	Tebbe
8858621	October 2014	Oba
8865202	October 2014	Zerbe et al.
8888745	November 2014	Van Der Graaf et al.
8926595	January 2015	Alessi et al.
8940316	January 2015	Alessi et al.
8992961	March 2015	Berry et al.
8992962	March 2015	Lautenbach et al.
9044209	June 2015	Dayton et al.
9078900	July 2015	Kuzma et al.
9095553	August 2015	Rohloff et al.
9241722	January 2016	Yu
D750764	March 2016	DeSocio
9332995	May 2016	Russo
9526763	December 2016	Rohloff et al.
9539200	January 2017	Lautenbach
9572889	February 2017	Alessi et al.
D789539	June 2017	Kleiner
D789540	June 2017	Gyorgy
9682127	June 2017	Alessi et al.
RE46577	October 2017	Collins
D805199	December 2017	Chen
D810289	February 2018	Jutila
9889085	February 2018	Alessi et al.
9931133	April 2018	Mirza
D816843	May 2018	Lewis
D819820	June 2018	Radau
2001/0012511	August 2001	Bezwada et al.
2001/0021377	September 2001	Jamiolkowski et al.
2001/0021822	September 2001	Ayer
2001/0022974	September 2001	Ayer
2001/0026793	October 2001	Jamiolkowski et al.
2001/0027311	October 2001	Chen et al.
2001/0031940	October 2001	Loos
2001/0031790	November 2001	Beisswenger
2001/0036472	November 2001	Wong et al.
2001/0040326	November 2001	Balczun
2002/0001631	January 2002	Okumu
2002/0004481	January 2002	Cleland et al.
2002/0012818	January 2002	Ruppi et al.
2002/0034532	March 2002	Brodbeck et al.
2002/0037309	March 2002	Jaworowicz et al.
2002/0048600	April 2002	Bhatt et al.
2002/0077599	June 2002	Wojcik
2002/0098180	July 2002	Lei
2002/0136848	September 2002	Yoshii et al.
2002/0137666	September 2002	Beeley et al.
2002/0141985	October 2002	Pittner et al.
2002/0197185	December 2002	Jamiolkowski et al.
2002/0197235	December 2002	Moran
2003/0007992	January 2003	Gibson et al.
2003/0032947	February 2003	Harper et al.
2003/0040699	February 2003	Talling
2003/0044467	March 2003	Brodbeck et al.
2003/0045454	March 2003	Okumu et al.
2003/0059376	March 2003	Libbey et al.
2003/0059471	March 2003	Compton et al.
2003/0060425	March 2003	Ahlem et al.
2003/0078618	April 2003	Fey et al.
2003/0097121	June 2003	Babcock et al.
2003/0104063	June 2003	Babcock et al.
2003/0108608	June 2003	Berry et al.
2003/0108609	June 2003	Berry et al.
2003/0113380	June 2003	Ramstack et al.
2003/0114837	June 2003	Peterson et al.
2003/0118660	June 2003	Rickey et al.
2003/0135153	July 2003	Hagemeier
2003/0138403	July 2003	Drustrup
2003/0138491	July 2003	Tracy et al.
2003/0157178	August 2003	Chen et al.
2003/0170289	September 2003	Chen et al.
2003/0180364	September 2003	Chen et al.
2003/0186858	October 2003	Arentsen
2003/0191099	October 2003	Bohlmann et al.
2003/0211974	November 2003	Brodbeck et al.
2003/0215515	November 2003	Truong-Le et al.
2003/0220617	November 2003	Dickerson
2003/0233101	December 2003	Lubock et al.
2004/0001689	January 2004	Goldsmith et al.
2004/0001889	January 2004	Chen et al.
2004/0002442	January 2004	Pan et al.
2004/0022859	February 2004	Chen et al.
2004/0024068	February 2004	Chen et al.
2004/0024069	February 2004	Chen et al.
2004/0029784	February 2004	Hathaway
2004/0039376	February 2004	Peery et al.
2004/0047888	March 2004	Kenison et al.
2004/0097906	May 2004	Fereira et al.
2004/0101557	May 2004	Gibson et al.
2004/0102762	May 2004	Gilbert
2004/0115236	June 2004	Chan et al.
2004/0142867	July 2004	Oi et al.
2004/0142902	July 2004	Stmijker-Boudier
2004/0151753	August 2004	Chen et al.
2004/0157951	August 2004	Wolf
2004/0198654	October 2004	Glaesner et al.
2004/0199140	October 2004	Rue
2004/0209801	October 2004	Brand et al.
2004/0215133	October 2004	Weber et al.
2004/0224903	November 2004	Berry et al.
2004/0225113	November 2004	LaFleur et al.
2004/0243106	December 2004	Ayer
2004/0265273	December 2004	Li et al.
2004/0266683	December 2004	Hathaway et al.
2004/0266692	December 2004	Young et al.
2005/0004557	January 2005	Russell
2005/0008661	January 2005	Fereira et al.
2005/0009742	January 2005	Bertilsson et al.
2005/0010196	January 2005	Fereira et al.
2005/0070883	March 2005	Brown et al.
2005/0070927	March 2005	Feinberg
2005/0079200	April 2005	Rathenow et al.
2005/0079202	April 2005	Chen et al.
2005/0010942	May 2005	Eliaz et al.
2005/0095284	May 2005	Trautman
2005/0101943	May 2005	Ayer et al.
2005/0106214	May 2005	Chen
2005/0112188	May 2005	Eliaz et al.
2005/0118206	June 2005	Luk et al.
2005/0118221	June 2005	Blakely et al.
2005/0131386	June 2005	Freeman et al.
2005/0131389	June 2005	Peterson et al.
2005/0143749	June 2005	Zalenski et al.
2005/0175701	August 2005	Pan et al.
2005/0201980	September 2005	Moran
2005/0215475	September 2005	Ong et al.
2005/0216087	September 2005	Zucherman et al.
2005/0266087	December 2005	Junnarkar et al.
2005/0271702	December 2005	Wright et al.
2005/0276856	December 2005	Fereira et al.
2005/0281879	December 2005	Chen et al.
2006/0013879	January 2006	Brodbeck et al.
2006/0014678	January 2006	Cowley et al.
2006/0030526	February 2006	Liu et al.
2006/0069029	March 2006	Kolterman et al.
2006/0073182	April 2006	Wong et al.
2006/0084604	April 2006	Kitaura et al.
2006/0084922	April 2006	Botha
2006/0094652	May 2006	Levy et al.
2006/0094693	May 2006	Aziz et al.
2006/0106399	May 2006	Taras et al.
2006/0141040	June 2006	Chen et al.
2006/0142234	June 2006	Chen et al.
2006/0160736	July 2006	Nadler
2006/0178304	August 2006	Juul-Mortensen et al.
2006/0193918	August 2006	Rohloff et al.
2006/0216242	September 2006	Rohloff et al.
2006/0224145	October 2006	Gills
2006/0233841	October 2006	Brodbeck et al.
2006/0246138	November 2006	Rohloff et al.
2006/0251618	November 2006	Dennis et al.
2006/0263433	November 2006	Ayer et al.
2006/0264890	November 2006	Moberg et al.
2006/0280795	December 2006	Penhasi et al.
2006/0293232	December 2006	Levy et al.
2007/0027105	February 2007	Junnarkar et al.
2007/0141102	June 2007	De Graaff et al.
2007/0149011	June 2007	Kent et al.
2007/0166352	July 2007	Wright et al.
2007/0207958	September 2007	Bridon et al.
2007/0248572	October 2007	Moran et al.
2007/0281024	December 2007	Lautenbach et al.
2008/0020016	January 2008	Li et al.
2008/0038316	February 2008	Wong et al.
2008/0064636	March 2008	Bloom et al.
2008/0065090	March 2008	Scribner et al.
2008/0091176	April 2008	Alessi et al.
2008/0110515	May 2008	Angelosanto et al.
2008/0112994	May 2008	Junnarkar et al.
2008/0200383	August 2008	Jennings et al.
2008/0207512	August 2008	Roth et al.
2008/0208194	August 2008	Bickenbach
2008/0226625	September 2008	Berry et al.
2008/0226689	September 2008	Berry et al.
2008/0260838	October 2008	Hokenson et al.
2008/0260840	October 2008	Alessi et al.
2008/0269725	October 2008	Deem et al.
2008/0312157	December 2008	Levy et al.
2009/0012463	January 2009	Beelen et al.
2009/0022727	January 2009	Houston et al.
2009/0036364	February 2009	Levy et al.
2009/0042781	February 2009	Petersen et al.
2009/0074734	March 2009	Rottiers
2009/0087408	April 2009	Berry et al.
2009/0125030	May 2009	Tebbe
2009/0156474	June 2009	Roth et al.
2009/0163447	June 2009	Maggio
2009/0186817	July 2009	Ghosh et al.
2009/0202481	August 2009	Li et al.
2009/0202608	August 2009	Alessi et al.
2009/0209460	August 2009	Young et al.
2009/0210019	August 2009	Kim et al.
2009/0215694	August 2009	Kolterman et al.
2009/0234392	September 2009	Dziedzic
2009/0247463	October 2009	Wright et al.
2009/0254143	October 2009	Tweden et al.
2009/0286723	November 2009	Levy et al.
2009/0312246	December 2009	Baron et al.
2010/0092566	April 2010	Alessi et al.
2010/0094252	April 2010	Wengreen et al.
2010/0105627	April 2010	Salama et al.
2010/0144621	June 2010	Kim et al.
2010/0185184	July 2010	Alessi et al.
2010/0297209	November 2010	Rohloff et al.
2010/0298807	November 2010	Jansen et al.
2010/0298840	November 2010	Schwartz
2010/0331868	December 2010	Bardy
2011/0076317	March 2011	Alessi et al.
2011/0091527	April 2011	Moonen et al.
2011/0104111	May 2011	Rohloff et al.
2011/0152181	June 2011	Alsina-Fernandez et al.
2011/0152182	June 2011	Alsina-Fernandez et al.
2011/0160708	June 2011	Berry et al.
2011/0166554	July 2011	Alessi et al.
2011/0264077	October 2011	Rohloff et al.
2011/0306549	December 2011	Tatarkiewicz et al.
2012/0178687	July 2012	Alessi et al.
2012/0208755	August 2012	Leung
2012/0265232	October 2012	Surbone
2012/0303045	November 2012	Cooper et al.
2013/0030417	January 2013	Alessi
2013/0034210	February 2013	Rohloff et al.
2013/0052237	February 2013	Eliaz et al.
2013/0296661	November 2013	Bornzin et al.
2013/0324977	December 2013	Vanderpool
2014/0058409	February 2014	Bratlie
2014/0058425	February 2014	Porat
2014/0121741	May 2014	Bennett et al.
2014/0148837	May 2014	Levitan
2014/0163057	June 2014	Patel et al.
2014/0236162	August 2014	Barongan
2014/0257272	September 2014	Clark, III et al.
2014/0324067	October 2014	Emken
2014/0378900	December 2014	Alessi et al.
2015/0111818	January 2015	Alessi et al.
2015/0057227	February 2015	Leung
2015/0133791	May 2015	Sato et al.
2015/0231062	August 2015	Lautenbach et al.
2015/0231256	August 2015	Berry et al.
2015/0297509	October 2015	Schwarz
2015/0359553	December 2015	Harnisch
2016/0022582	January 2016	Alessi et al.
2016/0030337	February 2016	Kuzma et al.
2016/0354115	December 2016	Smith
2016/0354305	December 2016	Alessi et al.
2017/0056476	March 2017	Rohloff et al.
2017/0079906	March 2017	Alessi et al.
2017/0119854	May 2017	Alessi et al.
2017/0119855	May 2017	Berry et al.
2017/0181964	June 2017	Lautenbach et al.
2017/0252409	September 2017	Leung
2017/0273706	September 2017	Mirza
2017/0319470	November 2017	Eliaz et al.
2017/0319662	November 2017	Berry et al.
2017/0348392	December 2017	Rohloff et al.
2017/0368145	December 2017	Alessi et al.
2018/0009871	January 2018	Blackwell et al.
2018/0193059	July 2018	Bae

Foreign Patent Documents

	000000635692		Sep 1936		DE
	0079405		May 1983		EP
	0254394		Jan 1988		EP
	0295411		Dec 1988		EP
	0304107		Feb 1989		EP
	0368339		May 1990		EP
	0373867		Jun 1990		EP
	0431942		Jun 1991		EP
	0486959		May 1992		EP
	0497575		Aug 1992		EP
	0521586		Jan 1993		EP
	0596161		May 1994		EP
	0379147		Sep 1994		EP
	0627231		Dec 1994		EP
	0631794		Jan 1995		EP
	0729747		May 1997		EP
	0771817		May 1997		EP
	0596161		Feb 1998		EP
	0841359		May 1998		EP
	0767689		Jun 1999		EP
	1046399		Oct 2000		EP
	1084703		Mar 2001		EP
	1300129		Apr 2003		EP
	1300173		Apr 2003		EP
	1300129		May 2003		EP
	1323450		Jul 2003		EP
	1600187		Jan 2009		EP
	2133073		Dec 2009		EP
	2020990		Sep 2010		EP
	640907		Jul 1928		FR
	2616665		Dec 1988		FR
	1049104		Nov 1966		GB
	1518683		Jul 1978		GB
	2138298		Nov 1986		GB
	2501400		Oct 2013		GB
	2501400		Oct 2013		GB
	H02124814		May 1990		JP
	H07196479		Aug 1995		JP
	1997/509346		Sep 1997		JP
	9241153		Sep 1997		JP
	11-100353		Apr 1999		JP
	2006/213727		Aug 2006		JP
	8901004		Nov 1990		NL
	9000948		Nov 1990		NL
	9100160		Aug 1992		NL
	9100160		Aug 1992		NL
	592113		Aug 2012		NZ
	200634060		Oct 2006		TW
	WO 1989/003678		May 1989		WO
	WO-1990/013285		Nov 1990		WO
	WO-1990/013361		Nov 1990		WO
	WO-1990/013780		Nov 1990		WO
	WO 91/07160		May 1991		WO
	WO-1992/019241		Nov 1992		WO
	WO 93/06819		Apr 1993		WO
	WO 93/06821		Apr 1993		WO
	WO 93/008832		May 1993		WO
	WO 93/09763		May 1993		WO
	WO 93/23083		Nov 1993		WO
	WO 94/09743		May 1994		WO
	WO-1994/010982		May 1994		WO
	WO 94/21262		Sep 1994		WO
	WO 95/01167		Jan 1995		WO
	WO 95/09006		Apr 1995		WO
	WO 95/09007		Apr 1995		WO
	WO 1995/013799		May 1995		WO
	WO 95/34285		Dec 1995		WO
	WO 96/001134		Jan 1996		WO
	WO 96/003116		Feb 1996		WO
	WO-1996/036317		Nov 1996		WO
	WO 96/39142		Dec 1996		WO
	WO 96/40049		Dec 1996		WO
	WO 96/40139		Dec 1996		WO
	WO 96/40355		Dec 1996		WO
	WO-1996/040049		Dec 1996		WO
	WO 97/15289		May 1997		WO
	WO 97/15296		May 1997		WO
	WO 97/28181		Aug 1997		WO
	WO-1997/031943		Sep 1997		WO
	WO-1997/044039		Nov 1997		WO
	WO 97/46204		Dec 1997		WO
	WO 97/47339		Dec 1997		WO
	WO 98/00152		Jan 1998		WO
	WO 98/00157		Jan 1998		WO
	WO 98/00158		Jan 1998		WO
	WO 98/02169		Jan 1998		WO
	WO-1997/041837		Feb 1998		WO
	WO-1998/007412		Feb 1998		WO
	WO 98/13091		Apr 1998		WO
	WO 98/13092		Apr 1998		WO
	WO 98/16250		Apr 1998		WO
	WO 98/17315		Apr 1998		WO
	WO 98/20930		May 1998		WO
	WO 98/27960		Jul 1998		WO
	WO 98/027962		Jul 1998		WO
	WO 98/27963		Jul 1998		WO
	WO 98/030231		Jul 1998		WO
	WO 98/32463		Jul 1998		WO
	WO-1998/030231		Jul 1998		WO
	WO 98/42317		Oct 1998		WO
	WO 98/47487		Oct 1998		WO
	WO 98/51282		Nov 1998		WO
	WO 98/58698		Dec 1998		WO
	WO 99/03453		Jan 1999		WO
	WO 99/04767		Feb 1999		WO
	WO 99/004768		Feb 1999		WO
	WO-1999/012549		Mar 1999		WO
	WO 99/16419		Apr 1999		WO
	WO 99/025728		May 1999		WO
	WO 99/29306		Jun 1999		WO
	WO 99/033446		Jul 1999		WO
	WO 99/33449		Jul 1999		WO
	WO 99/39700		Aug 1999		WO
	WO 99/040788		Aug 1999		WO
	WO 99/044659		Sep 1999		WO
	WO 99/062501		Dec 1999		WO
	WO 99/064061		Dec 1999		WO
	WO 00/013663		Mar 2000		WO
	WO 00/029206		May 2000		WO
	WO 00/038652		Jul 2000		WO
	WO 00/039280		Jul 2000		WO
	WO 00/040273		Jul 2000		WO
	WO 00/041548		Jul 2000		WO
	WO 00/045790		Aug 2000		WO
	WO 00/054745		Sep 2000		WO
	WO-2000/059476		Oct 2000		WO
	WO 00/066138		Nov 2000		WO
	WO 00/067728		Nov 2000		WO
	WO-2000/066087		Nov 2000		WO
	WO-2001/019345		Mar 2001		WO
	WO 01/28631		Apr 2001		WO
	WO-2001/028525		Apr 2001		WO
	WO 01/043528		Jun 2001		WO
	WO 01/051041		Jul 2001		WO
	WO 01/68168		Sep 2001		WO
	WO 01/78683		Oct 2001		WO
	WO 02/028366		Apr 2002		WO
	WO 02/036072		May 2002		WO
	WO 02/043800		Jun 2002		WO
	WO 02/045752		Jun 2002		WO
	WO 02/47716		Jun 2002		WO
	WO 02/067895		Sep 2002		WO
	WO 02/069983		Sep 2002		WO
	WO 02/76344		Oct 2002		WO
	WO 02/085428		Oct 2002		WO
	WO 03/000230		Jan 2003		WO
	WO 03/007981		Jan 2003		WO
	WO 03/011892		Feb 2003		WO
	WO 03/024357		Mar 2003		WO
	WO 03/024503		Mar 2003		WO
	WO-2003/020245		Mar 2003		WO
	WO 03/030923		Apr 2003		WO
	WO 03/041684		May 2003		WO
	WO 03/041757		May 2003		WO
	WO 03/053400		Jul 2003		WO
	WO-2003/066585		Aug 2003		WO
	WO 03/072113		Sep 2003		WO
	WO 03/072133		Sep 2003		WO
	WO 04/002565		Jan 2004		WO
	WO 2004/026106		Apr 2004		WO
	WO-2004/034975		Apr 2004		WO
	WO-2004/035754		Apr 2004		WO
	WO-2004/035762		Apr 2004		WO
	WO 2004/036186		Apr 2004		WO
	WO 04/046338		Jun 2004		WO
	WO 04/052336		Jun 2004		WO
	WO 04/056338		Jul 2004		WO
	WO 04/089335		Oct 2004		WO
	WO 2004/089458		Oct 2004		WO
	WO-2004/103342		Dec 2004		WO
	WO 05/048930		Jun 2005		WO
	WO 05/048952		Jun 2005		WO
	WO 05/102293		Nov 2005		WO
	WO 2005/102293		Nov 2005		WO
	WO-2005/110425		Nov 2005		WO
	WO 06/017772		Feb 2006		WO
	WO 06/023526		Mar 2006		WO
	WO 2006/077242		Jul 2006		WO
	WO 2006/077250		Jul 2006		WO
	WO 06/081279		Aug 2006		WO
	WO 06/083761		Aug 2006		WO
	WO 06/084139		Aug 2006		WO
	WO 06/086727		Aug 2006		WO
	WO 06/101815		Sep 2006		WO
	WO 06/111169		Oct 2006		WO
	WO-2006/131730		Dec 2006		WO
	WO 07/024700		Mar 2007		WO
	WO 07/056681		May 2007		WO
	WO 07/075534		Jul 2007		WO
	WO 07/084460		Jul 2007		WO
	WO 2007/082889		Jul 2007		WO
	WO 07/133778		Nov 2007		WO
	WO 07/140416		Dec 2007		WO
	WO 08/021133		Feb 2008		WO
	WO-2008/041245		Apr 2008		WO
	WO 08/061355		May 2008		WO
	WO-2008/086086		Jul 2008		WO
	WO 08/133908		Nov 2008		WO
	WO 08/134425		Nov 2008		WO
	WO 09/109927		Sep 2009		WO
	WO-2009/143285		Nov 2009		WO
	WO 2010/045169		Apr 2010		WO
	WO 2013/004983		Jan 2013		WO
	WO 2013/184235		Dec 2013		WO

Other References

Croxatto. "Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant." Eur J Contracept Reprod Health Care. Sep. 2000; 5 Suppl 2:21-8. cited by applicant . Implanon_Prescribing Information. Manufactured for Merck Sharp & Dohme Corp. Copyright .COPYRGT. 2006, 2009, 2012 Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016. cited by applicant . Nexplanon_Prescribing Information. Manufactured for Merck Sharp & Dohme Corp. Copyright .COPYRGT. 2011 Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016. cited by applicant . Probuphine_Prescribing Information. Distributed by Braeburn Pharmaceuticals, Inc. Revised May 2016. cited by applicant . International Search Report and Written Opinion for PCT Application No. PCT/US2016/035602 dated Nov. 29, 2016. cited by applicant . Adolf, "Human interferon omega-a review," Mult. Sclr. 1:S44-47 (1995). cited by applicant . Costantino et al., "Protein Spray Freeze Drying. 2. Effect of Formulation Variables on particle Size and Stability," J. Pharm. Sci. 91:388-395 (2002). cited by applicant . Henry et al., "Comparing ITCA 650, continuous subcutaneous delivery of exenatide via Duros.RTM. device, vs. twice daily exenatide injections in metformin-treated type 2 diabetes," oral presentation at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden , 21 pages (Sep. 20-24, 2010). cited by applicant . Huggins et al., "Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses," Antimicrobial Agents & Chemotherapy, 26(4):476-480 (1984). cited by applicant . Ishiwata et al., "Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs," J. Vet. Med. Sci. 60(8):911-917 (1998). cited by applicant . Johnson et al., "How interferons fight disease," Sci. Am. 270(5):68-75 (May 1994). cited by applicant . Lublin et al., "Defining the clinical course of multiple sclerosis: results of an international survey," Neurology. 46:907-911 (1996). cited by applicant . Madsbad, "Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results," Best Practice & Research Clinical Endocrinology & Metabolism 23:463-77 (2009). cited by applicant . Nielsen, "Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes," Drug Discovery Today 10(10):703-710 (May 15, 2005). cited by applicant . Patti et al., "Natural interferon-b treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients: two-year study," Acta. Neurol. Scand. 100:283-289 (1999). cited by applicant . Paty et al., "Interferon beta-1 b is effective in relapsing-remitting multiple sclerosis," Neurology 43:662-667 (1993). cited by applicant . PCT International Search Report for PCT/US2009/000916, 4 pages (dated Aug. 12, 2009). cited by applicant . "Intarcia Therapeutics Announces Final Results from a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1," NLV Partners Press Coverage Portfolio News (Apr. 12, 2007) (Press Release). cited by applicant . Quianzon et al., "Lixisenatide-Once-daily Glucagon-like Peptide-1 Diabetes," US Endocrinology 7(2):104-109 (2011). cited by applicant . Ratner et al., "Dose-dependent effects of the one-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfmmin: a randomized, double-blind, placebo-controlled trial," Diabetic Medicine 27(9):1024-1032 (Sep. 2010). cited by applicant . Roberts et al., "The Evolution of the Type I Interferonsl," J. Interferon Cytokine Res. 18(10):805-816 (Oct. 1998). cited by applicant . Rohloff et al., "DUROS Technology Delivers Peptides and Proteins at Consistent Rate Continuously for 3 to 12 Months," J. Diabetes Sci. & Tech., 2(3):461-467 (May 1, 2008). cited by applicant . "Sequence Listings for International Patent Application Publication No. WO2009109927, WIPO Patentscope", http://patentscope.wipoint/search/docservicepdf_pct/id00000008776887, 1 page (last visited Nov. 14, 2012). cited by applicant . Shire et al., "Challenges in the Development of High Protein Concentration Formulations," J. Pharm. Sci. 93:1390-1402 (2004). cited by applicant . Smith, "Peripheral Neuro-hormones as a Strategy to Treat Obesity," oral presentation at the 2007 Cardiometabolic Health Congress in Boston, MA, pp. 1-35 (Sep. 26-29, 2007). cited by applicant . Written Opinion for International Patent Application No. PCT/US2009/005629 (corresponding to U.S. Appl. No. 12/587,946), 5 pages (dated Apr. 15, 2011). cited by applicant . Zhang et al., "Efficacy observations of different dosages of interferon to treat 150 Hepatitis B carriers," Current Physician 2(12):45-46 (1997). cited by applicant . Pratley et al., "Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors," Rev. Diabet. Stud., 5(2):73-94 (2008). cited by applicant . Gonzalez, et al., "Hemoglobin Alc: A Reliable and Accurate Test for Diabetes Care? A Prospective Study in Mexico," Salud Publica Mex 55:462-468 (2013). cited by applicant . Ahn et al., "A New Approach to Search for the Bioactive Confirmation of Glucagon: Positional Cyclization Scanning" Journal of Medicinal Chemistry, vol. 44, No. 19, (2001): 3109-3116. cited by applicant . "Abstracts 2007," Diabetologia Clinical & Experimental Diabetes & Metabolism, Springer, Berlin, Germany, vol. 50 S243 (Aug. 21, 2007) (paragraph [0586]) (XP002538652). cited by applicant . Jetschmann et al., "Open-label rising-dose study of omega interferon in IFN-naive patients with chronic hepatitis C," Gastroenterology 122:A278-A347 (Apr. 1, 2002) (Abstract M1454). cited by applicant . Bray, "Gut Signals and Energy Balance: Ghrelin, Peptide YY, Leptin, and Amylin," (Dec. 19, 2007) (slides and transcript for presentation at Medscape CME). cited by applicant . "Implantable infusion pumps: technology poised for takeoff," BBI Newsletter 17(12):209211 (Dec. 1994). cited by applicant . "Search Report and Written Opinion" dated Dec. 19, 2008 for PCT/US2008/005235, filed Apr. 22, 2008. cited by applicant . Adamson et al., "Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer," J. Clin. Oncol. 15(11):3330-3337 (Nov. 1997). cited by applicant . Adolf et al., "Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) .omega.1: evidence that IFN-.omega.1 is a component of human leukocyte IFN," Virology 175(2):410-471 (Apr. 1990). cited by applicant . Adolf et al., "Antigenic structure of human interferon .omega.1 (Interferon .alpha.ll 1): comparison with other human interferons," J. Gen. Virol. 68(6):1669-1676 (Jun. 1987). cited by applicant . Adolf et al., "Purification and characterization of natural human interferon .omega.l," J. Bio. Chem. 265(16):9290-9295 (Jun. 1990). cited by applicant . Adolf et al., "Human interferon .omega.l: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein," Biochim. Biophys. Acta 108(9):167-174 (Jun. 1991). cited by applicant . Andrx Pharmaceuticals, LLC, ANDA for Concerta.RTM. Extended-Release Tablets, 6 pages (correspondence dated Sep. 6, 2005). cited by applicant . ASTM International, Annual Book of ASTM Standards, 8.02:208-211, 584-587 (1984). cited by applicant . Ansel et al., "Dosage Form Design: Pharmaceutical and Formulation Considerations," Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 3 at 87-92 (7th ed. Lippincott Williams & Wilkins 1999). cited by applicant . Ansel et al., "Modified-Release Dosage Forms and Drug Delivery Systems," Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 8 at 229-243 (7th ed. Lippincott Williams & Wilkins 1999). cited by applicant . Aulitzky, " Successful Treatment of Metastatic Renal Cell Carcinoma With a Biologically Active Dose of Recombinant Interferon-Gama," Journal of Clinical Oncology 7(12):1875-1884 (1989). cited by applicant . Hauck, "Engineer's Guide to Plastics," Materials Engineering 5(72):38-45 (Jul. 17, 1972). cited by applicant . Bailon et al., "Rational Design of a Potent, Long-lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-conjugated Interferon Alpha-2a for the Treatment of Hepatitis C," Bioconjugate Chemistry 12(2):195-202 (2001). cited by applicant . Bakan et al., "Physicochemical Characterization of a Synthetic Lipid Emulsion for Hepatocyte-Selective Delivery of Lipophilic Compounds: Application to Polyiodinated triglycerides as Contrast Agents for Computed Tomography," J. Pharm. Sci., 85(9):908-914 (1996). cited by applicant . Bakhtiar et al, "Taking Delivery," Soap Perfumery & Cosmetics 76(3):59-65 (2003) (liposomes in cosmetic delivery systems). cited by applicant . Balkwill,F., "Interferons," Lancet 1(8646):1060-1063 (May 1989). cited by applicant . Bauer et al., "Non-aqueous emulsions as vehicles for capsule fillings," Drug Dev. & Industrial Pharmacy 10(5):699-712 (1984). cited by applicant . Bekkering et al., "Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model," Hepatology 33(2):419-423 (Feb. 2001). cited by applicant . Bell et al., "Hamster preproglucagon contains the sequence of glucagon and two related peptides," Nature 302:716-718 (1983). cited by applicant . Bell et al, "Impact of moisture on thermally induced denaturation and decomposition of lyophilized bovine somatotropin," Drug Delivery Research & Dev. Biopolymers, (35):201209 (1995). cited by applicant . Bertoncello et al., "Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil," Int. J. Radiat. Biol. 67(1):57-64 (1995). cited by applicant . Bohlinder et al., "Use and characteristics of a novel lipid particle-forming matrix as a drug-carrier system," Euro. J. Pharm. Sci. 2(4):271-279 (1994). cited by applicant . Bolinger et al., "Recombinant interferon .gamma. for treatment of chronic granulomatous disease and other disorders," Clin. Pharm. 11(10):834-850 (Oct. 1992). cited by applicant . Bonkovsky et al., "Outcomes research in chronic viral hepatitis C: effects of interferon therapy," Can. J. Gastroenterol. 14(Supp. B):21B-29B (Jul.-Aug. 2000). cited by applicant . Borden et al., "Second-generation interferons for cancer: clinical targets," Semin. Cancer Biol. 10(2):125-144 (Apr. 2000). cited by applicant . Boue et al., "Antiviral and antiluteolytic activity of recombinant bovine IFN-.omega.1 obtained from Pichia pastoris," J. Interferon & Cytokine Res. 20:677-683 (2000). cited by applicant . Buckwold et. al. "Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses," Antiviral Res. 73(2):118-25 (Feb. 2007) (Epub Sep. 11, 2006). cited by applicant . Cantor, "Theory of lipid monolayers comprised of mixtures of flexible and stiff amphiphiles in anthermal solvents: fluid phase coexistence," J. Chem. Physics 104(20):8082-8095 (1996). cited by applicant . CAS Number: 56-81-5 (Nov. 16, 1984). cited by applicant . Chang et al., "Biodegradable polyester implants and suspension injection for sustained release of a cognitive enhancer," Pharm. Tech. 20(1):80-84 (1996). cited by applicant . Chapman et al., "Physical Studies of Phospholipids. VI. Thermotropic and Lyotropic Mesomorphism of Some 1,2-Diacylphosphatidylcholines (lecithins)," Chem. & Physics of Lipids 1(5):445-475 (1967). cited by applicant . Chaumeil, "Micronization: a method of improving the bioavailability of poorly soluble drugs," Methods & Findings in Experimental & Clinical Pharmacology 20(3):211-215 (1998). cited by applicant . Clark et al., "The diabetic Zucker fatty rat," Proc. Soc. Exp. Biol. 173(1):68-75 (1983). cited by applicant . Condino-Neto, "Interferon-.gamma. improves splicing efficiency of CYBB gene transcripts in an interferon responsive variant of chronic granulomatous disease due to a splice site consensus region mutation," Blood 95(11):3548-3554 (Jun. 2000). cited by applicant . Darney, "Subdermal progestin implant contraception," Current Opinion in Obstetrics & Gynecology 3:470-476 (1991). cited by applicant . Das et al., "Reviewing Antisense Oligonucleotide Therapy: Part 2, Delivery Issues," BioPharm, 2(11):44-51 (1999). cited by applicant . Dash et al., "Therapeutic applications of implantable drug delivery systems," Journal of Pharmacological and Toxicological Methods, 40(1):1-12 (1998). cited by applicant . Davis et al., "Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 570). cited by applicant . Deacon et al., "GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion," Am. J. Physiol. Endocrinol. Metab., 282:E873-E879 (2002). cited by applicant . Desai et al., "Protein structure in the lyophilized state: a hydrogen isotope exchange/NMR study with bovine pancreatic trypsin inhibitor," J. Am. Chem. Soc. 116(21):9420-9422 (1994). cited by applicant . Di Marco et al., "Combined treatment of relapse of chronic hepatitis C with high-dose .alpha.-2B interferon plus ribavirin for 6 or 12 months," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 569). cited by applicant . Dorr et al., "Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days," J. Interferon Res. 8:717-725 (1988). cited by applicant . Uhlig et al., "The electro-osmotic actuation of implantable insulin micropumps," J. Biomed. Materials Res. 17:931-943 (1983). cited by applicant . Efendic et al., "Overview of incretin hormones," Honn. Metab. Res., 36(11-12):742-746 (2004). cited by applicant . Eissele et al., "Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide," Life Sci., 55(8):629-634 (1994). cited by applicant . Elias et al., "Infusional Interleukin-2 and 5-fluorouracil with subcutaneous interferon-.alpha. for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study," Cancer 89(3):597-603 (Aug. 2000). cited by applicant . Eng et al., "Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas," J. Biol. Chem., 267(11):7402-7405 (1992). cited by applicant . Eng et al., "Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom," J. Biol. Chem., 265(33):20259-20262 (1990). cited by applicant . Eppstein et al., "Biological activity of liposome-encapsulated murine interferon .gamma. is mediated by a cell membrane receptor," PNAS USA 82:3688-3692 (1985). cited by applicant . Eros et al., "Multiple phase emulsions as controlled drug delivery therapeutic systems," Proc.-Conf. Colloid Chem. 193-196 (1993). cited by applicant . Fang et al., "The impact of baseline liver histology on virologic response to interferon .alpha.-2b.+-..rho. ribavirin therapy in patients with chronic hepatitis C," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 572). cited by applicant . Felker et al., "The Rate of Transfer of Unesterified Cholesterol from Rat Erythrocytes to Emulsions Modeling Nascent Triglyceride-Rich Lipoproteins and Chylomicrons Depends on the Degree of Fluidity of the Surface," J. Nutritional Biochem. 4(1):630-634 (1993). cited by applicant . Ferenci et al, "Combination of interferon (IFN) induction therapy and ribavirin in chronic hepatitis C," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 977). cited by applicant . Fontaine et al., "Recovery from chronic hepatitis C in long-term responders to ribarivin plus interferon .beta.," Lancet 356(9223):41 (Jul. 2000). cited by applicant . Franchetti et al., "Furanfurin and Thiophenfurin: Two Novel Tiazofurin Analogues. Synthesis, Structure, Antitumor Activity, and Interactions with Inosine Monophosphate Dehydrogenase," J. Medicinal Chem. 38(19):3829-3837 (1995). cited by applicant . Fujii et al., "Effect of phosphatidylcholine on Skin Permeation of Indomethacin from gel prepared with Liquid Paraffin and Hydrogenated Phospholipid," Int'l J. Pharmaceutics 222(1):57-64 (2001). cited by applicant . Fujii et al., "Enhancement of skin permeation of miconazole by phospholipid and dodecyl 2-(N, N-dimethylamino) propionate (DDAIP)," Int'l J. Pharmaceutics 234(1-2):121-128 (2002). cited by applicant . Luft et al., "Electro-osmotic valve for the controlled administration of drugs," Med. & Biological Engineering & Computing 45-50 (Jan. 1978) (non-English with English abstract). cited by applicant . Gan To Kagaku Ryoho, "Phase II study of recombinant leukocyte A interferon (Ro22-8181) in malignant brain tumors," Cancer & Chemotherapy 12(4):913-920 (Apr. 1985) (non-English with English abstract). cited by applicant . Gappa et al., "Juvenile laryngeal papillomatosis--a case report," Pneurnologie 45(11):936-938 (Nov. 1991) (XP009079028) (non-English with English abstract). cited by applicant . Gause et al., "Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer," J. Clin. Oncol. 14(8):2234-2241 (Aug. 1996). cited by applicant . Ghiglione et al., "How glucagon-like is glucagon-like peptide-1?" Diabetologia 27:599-600 (1984). cited by applicant . Glue et al., "A dose-ranging study of Peg-intron and ribavirin in chronic hepatitis C--safety, efficacy, and virological rationale," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX(Nov. 5-9, 1999)(Abstract 571). cited by applicant . Goke et al., "Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells," J. Biol. Chem., 268(26):19650-19655 (1993). cited by applicant . Gonzales et al., "Randomized controlled trial including an initial 4-week `induction` period during one year of high-dose interferon .alpha.-2B treatment for chronic hepatitis C," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 975). cited by applicant . Gosland et al., "A phase I trial of 5-day continuous infusion cisplatin and interferon alpha," Cancer Chemother. Pharrnacol. 37(1-2):39-46 (1995). cited by applicant . Grant et al., "Combination therapy with interferon-.alpha. plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study," J. Med. Virol. 61(4):439-442 (Aug. 2000). cited by applicant . Gutniak et al., "Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus," N. Engl. J. Med., 326(20):1316-1322 (1992). cited by applicant . Hageman, "The Role of Moisture in Protein Stability, " Drug Dev. & Ind. Pharm. 14(14):2047-2070 (1988). cited by applicant . Heathcote et al., "Peginterferon alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis," New England J. Med. 343(23) 1673-1680 (2000). cited by applicant . Heim et al., "Intracellular signaling and antiviral effects of interferons," Dig. Liver Dis. 32(3):257-263 (Apr. 2000). cited by applicant . Heinrich et al., "Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid," Endocrinol., 115:2176-2181 (1984). cited by applicant . Hellstrand et al., "Histamine and cytokine therapy," Acta Oncol. 37(4):347-353 (1998). cited by applicant . Hellstrand et al., "Histamine and the response to IFN-.alpha. in chronic hepatitis C," Interferon Cytokine Res. 18(1):21-22 (Jan. 1998). cited by applicant . Hellstrand et al., "Histamine in immunotherapy of advanced melanoma: a pilot study," Cancer Immunol Immunother. 39(6):416-419 (Dec. 1994). cited by applicant . Hisatomi et al., "Toxicity of polyoxyethylene hydrogenated castor oil 60 (HCO-60) in experimental animals," J. Toxicol. Sci., 18(3):1-9 (1993). cited by applicant . Hodoshima et al., "Lipid nanoparticles for delivering antitumor drugs," International Journal of Pharmaceutics, 146(1):81-92 (1997). cited by applicant . Hoffmann-La Roche Inc., Pegasys.RTM. (peginterferon alfa-2a), 15 pages (2002). cited by applicant . Horton et al., "Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice" Cancer Res 59(16):4064-4068 (Aug. 1999). cited by applicant . Hubel et al., "A phase I/II study of idarubicin, dexamethasone and interferon-alpha (1-Dexa) in patients with relapsed or refractory multiple myeloma" Leukemia 11 Suppl 5:S47-S51 (Dec 1997). cited by applicant . Iacobelli et al., "A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer," Am. J. Clin. Oncol. 18(1):27-31 (1995). cited by applicant . IFNB Multiple Sclerosis Study Group, "Interferon.beta.-1b is effective in relapsing-remitting multiple sclerosis," Neurology 43(4):655-667 (Apr. 1993). cited by applicant . Intermune.RTM. Inc., Infergen.RTM. (Interferon alfacon-1), 5 pages (2002). cited by applicant . "Introduction to Antibodies", http://www.chemicon.com/resource/ANT101/a1.asp, 8 pages (retrieved May 2, 2007). cited by applicant . Isaacs et al., "Virus interference. I. The interferon," Pro. R. Soc. Lond. B. Biol. Sci. 147:258-267 (1957). cited by applicant . Jain et M., "Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system," J. Microencapsulation 17(3):343-362 (2000). cited by applicant . Jordan et al., "Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present and Future Recommendations," The Oncologist 12(9):11431150 (2007). cited by applicant . Kabalnov et al., "Macroemulsion type and stability of alkane-water-phospholipid systems," Abstracts of Papers, Part 1, 210th ACS National Meeting, 0-8412-3222-9, American Chemical Society, Chicago, IL (Aug. 20-24, 1995) (Abstract only). cited by applicant . Kabalnov et al., "Phospholipids as Emulsion Stabilizers.2. Phase Behavior Versus Emulsion Stability," Journal of Colloid and Interface Science 184(1):227-235 (1996). cited by applicant . Khalili et M., "Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C," Am. J. Gastroenterol. 95(5):1284-1289 (May 2000). cited by applicant . Kildsig et al., "Theoretical Justification of Reciprocal Rate Plots in Studies of Water Vapor Transmission through Films," J. Pharma. Sci. 29(11):1634-01637 (Nov. 17, 1970). cited by applicant . Kirkwood et al., "Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," J. Clin. Oncol. 14(1):7-17 (1996). cited by applicant . Kita et al., "Characterization of a polyethylene glycol conjugate of recombinant human interferon-.gamma.," Drug Des. Deliv. 6(3):157-0167 (Sep. 1990). cited by applicant . Knepp et al, "Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor," J. Pharm. Sci. Tech. 50(3):163-171 (1996). cited by applicant . Knepp et al., "Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures," Phanna. Res. 15(7):1090-1095 (1998). cited by applicant . Knobler et al., "Systemic .alpha.-interferon therapy of multiple sclerosis," Neurology 34(10):1273-1279 (Oct. 1984). cited by applicant . Kovacevic et al., "Treatment of chronic viral hepatitis B in secondary membranoproliferative glomerulonephritis using recombinant .alpha.-2 interferon," Maksic Dj Vojnosanit. Pregl. 57(2):235-240 (Mar.-Apr. 2000) (non-English with English abstract). Abs. cited by applicant . Kracke et al., "Mx proteins in blood leukocytes for monitoring interferon .beta.-lb therapy in patients with MS," Neurology 54(1):193-199 (Jan. 2000). cited by applicant . Kronenberger et al., "Influence of interferon-.alpha. on CD82-expression in HCV-positive patients," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 976). cited by applicant . Krown et al., "Interferons and interferon inducers in cancer treatment," Semin. Oncol. 13(2):207-217 (1986). cited by applicant . Kubes et al., "Cross-species antiviral and antiproliferative activity of human interferon-.omega.," J. Interferon Res. 14:57-59 (1994). cited by applicant . Kunzi et al., "Role of interferon-stimulated gene ISG-15 in the interferon-.omega.-mediated inhibition of human immunodeficiency virus replication," J. Interferon Cytokine Res. 16(11):919-927 (Nov. 1996). cited by applicant . Larsson, "Stability of emulsions formed by polar lipids," Progress in the Chemistry of Fats and Other Lipids 16:163-0169 (1978). cited by applicant . Lee et al., "Dynamics of hepatitis C virus quasispecies turnover during interferon-A treatment," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 974). cited by applicant . Lee, "Therapy of hepatitis C: interferon alfa-2A trials," Hepatology 26: 89S-95S (Sep. 1997) (XP000981288). cited by applicant . Lopez et al., "Manunalian pancreatic preproglucagon contains three glucagon-related peptides," Proc. Natl. Acad. Sci. USA, 80(18):5485-5489 (1983). cited by applicant . Lukaszewski et al., "Pegylated .alpha. interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on host immune response to infection," J. Virol. 74(11):5006-5015 (Jun. 2000). cited by applicant . Lund et al., "Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem," Proc. Natl. Acad. Sci. USA, 79(2):345-349 (1982). cited by applicant . Lundberg, "A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol)," J. Pharm. & Pharmacol. 49(1):16-21 (1997). cited by applicant . Magnuson et al. "Enhanced recovery of a secreted mammalian protein from suspension culture of genetically modified tobacco cells," Protein Expression & Purification 7:220-228 (1996). cited by applicant . Malley et al., "Chronic Toxicity and Oncogenicity of N-Methylpyrrolidone (Nmp) in Rats and Mice by Dietary Administration," Drug Chem Toxicol. 24(4):315-38 (Nov. 2001). cited by applicant . Manning et al, "Stability of protein pharmaceuticals," Pharm. Res. 6(11):903-918 (1989). cited by applicant . Marincola et al., "Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer," J. Clinical Oncol. 13(5):1110-1122 (1995) (XP009078965). cited by applicant . Massey, "Interaction of vitamin E with saturated phospholipid bilayers," Biochem. & Biophys. Res. Comms. 106(3):842-847 (1982). cited by applicant . McHutchison et al., "Interferon .alpha.-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C," N. Engl J Med. 339(21):1485-1492 (Nov. 1998). cited by applicant . McHutchison et al., "Open-label phase 1B study of hepatitis C viral dynamics with omega interferon treatment," Hepatology 34(4):A333 (Oct. 1, 2001) (XP004716177) (Abstract Only). cited by applicant . Meier et al., "The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans," Am. J. Physiol. Endocrinol. Metab., 290(6):E1118-E1123 (2006). cited by applicant . Merad et al., "Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-.alpha. plus IL-2 and IL-12)," J. Immunother. 23(3):369-378 (May-Jun. 2000). cited by applicant . Milella et al., "Neutralizing antibodies to recombinant .alpha.-interferon and response to therapy in chronic hepatitis C infection," Liver 13(3):146-150 (Jun. 1993). cited by applicant . Mohler, "Primer on electrodeposited coatings," Materials Engineering 5:38-45 (1972). cited by applicant . Mojsov, "Structural requirements for biological activity of glucagon-like peptide-I," Int. J. Peptide Protein Research, 40:333-343 (1992). cited by applicant . Morgan, "Structure and Moisture Permeability of Film-Forming Poloyers," Ind. Eng. Chem. 45(10):2296-2306 (1953). cited by applicant . Motzer et al., "Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma," J. Clinical Oncol. 19(5):1312-1319 (2001). cited by applicant . Nauck et al., "Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients," Diabet. Med., 15(11):937-945(1998). cited by applicant . Neumann et al., "Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-alpha Therapy," Science 282:103-107 (Dec. 1998). cited by applicant . Nieforth et al., "Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon-.alpha.-2a and a polyethylene glycol-modified derivative in healthy subjects," Clin. Pharmacol. Ther. 59(6):636-646 (Jun. 1996). cited by applicant . Norden et al., "Physicochemical characterization of a drug-containing phospholipid-stabilized o / w emulsion for intravenous administration," Eur. J. Phann. Sci. 13(4).393-401 (2001). cited by applicant . Olaso et al., "Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C," Esp. Quimioter. 12(3):220-228 (Sep. 1999) (non-English with English abstract). cited by applicant . Ortiz et al., "A differential scanning calorimetry study of the interaction of .alpha.-tocopherol with mixtures of phospholipids," Biochim et Biophys Acta 898(2):214-222 (1987). cited by applicant . Panitch, "Interferons in multiple sclerosis," Drugs 44(6):946-962 (Dec. 1992). cited by applicant . Patzelt et al., "Identification and processing of proglucagon in pancreatic islets," Nature, 282:260-266 (1979). cited by applicant . Peterson et al., "Zucker Diabetic Fatty Rat as a Model for Non-insulin-dependent Diabetes Mellitus," ILAR Journal, 32(3):16-19 (1990). cited by applicant . Peterson et al., "Neuropathic complications in the Zucker diabetic fatty rat (ZDF/Drt-fa)," Frontiers in diabetes research. Lessons from Animal Diabetes III, Shafrir, E. (ed), pp. 456-458, Smith-Gordon, London (1990). cited by applicant . Pimstone et al., "High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for hepatitis C," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 973). cited by applicant . Plauth et al, "Open-label phase II study of omega interferon in previously untreated HCV infected patients," Hepatology 34(4):A331 (Oct. 1, 2001) (XP004716169) (Abstract Only). cited by applicant . Plauth et al, "Open-label study of omega interferon in previously untreated HCV-infected patients," J. Hepatology 36(Supp. 1):125 (Apr. 2002) (XP002511882) (Abstract Only). cited by applicant . Pohl et al., "Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues," J. Biol. Chem., 273(16):9778-9784 (1998). cited by applicant . Poynard et al., "Is an `a la carte` combined interferon .alpha. 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C," Hepatology 31(1):211-218 (Jan. 2000). cited by applicant . Poynard et al., "Randomized trial of interferon .alpha. 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon .alpha. 2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus," Lancet 352(9138):1426-1432 (Oct. 1998). cited by applicant . "Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD," Intarcia Therapeutics, Inc. (Sep. 22, 2010) (Press Release). cited by applicant . Quesada et al., "Interferons in Hematological Malignancies", eds. Baron et al., U. Tex. 487-495 (1987). cited by applicant . Quintanar-Guerrero et al., "Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides," Pharm. Res. 14(2):119-127 (1997). cited by applicant . Rajkumar et al., "Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma," Int'l J. Radiat. Oncol. Biol. Phys. 40(2):297-302 (Jan. 15, 1998). cited by applicant . Roche Pharmaceuticals, Roferon.RTM.-A (Interferon alfa-2a, recombinant), 22 pages (2003). cited by applicant . Roff et al., "Handbook of Common Polymers", Cleveland Rubber Co. 72 pages (1971). cited by applicant . Rogers et al., "Permeability Valves," Ind. & Eng. Chem. 49(11):1933-1936 (Nov. 17, 1957). cited by applicant . Roman et al., "Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, Cremophor EL," Transplantation 48(4):554-558 (1989). cited by applicant . Roth et al., "High Dose Etretinate and Interferon-alpha--A Phase I Study in Squamous Cell Carcinomas and Transitional Cell Carcinomas," Acta Oncol. 38(5):613-617 (1999). cited by applicant . Roth et al., "Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity," Endocrinol. 148(12):6054-61 (Dec. 2007). cited by applicant . Schepp et al., "Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2," Eur. J. Pharmacol., 269(2):183-191 (1994). cited by applicant . Schering Corp., Intron.RTM. A for Injection, 6 pages (2001). cited by applicant . Schering Corp., PEG-Intron.TM. (Peginterferon alfa-2b) Powder for Injection, 29 pages (2003). cited by applicant . Schmalfub et al., "Modification of drug penetration into human skin using microemulsions," J. Controlled Release 46(3):279-285 (1997). cited by applicant . Sen et al., "The interferon system: a bird's eye view of its biochemistry," J. Biol. Chem. 267(8):5017-5020 (Mar. 1992). cited by applicant . Shiffman et al., "A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999) (Abstract 567). cited by applicant . Shima et al., "Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment," J. Gastroenterol. Hepato). 15(3):294-299 (Mar. 2000). cited by applicant . Shiratori et al., "Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy," Ann. Int. Med. 132(7):517-524 (Apr. 2000). cited by applicant . Simon et al., "A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon .beta.1a," Neurology 55(2):185-192 (Jul. 2000). cited by applicant . Sparks et al., "Lipoprotein alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia," Metabolism, 47(11):1315-1324 (1998). cited by applicant . Sulkowski et al., "Pegylated Interferon Alfa-2A (Pegasys.TM.) and Ribavirin Combination Therapy for Chronic Hepatitis C: A Phase II Open-Label Study," Gastroenterology 118(4, Supp. 2) (2000) (Abstract 236). cited by applicant . Sulkowski et al., "Peginterferon-.alpha.-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study," Biodrugs 16(2):105-109 (2002). cited by applicant . Talpaz et al., "Phase I study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia," Blood 98(6):1708-1713 (2001). cited by applicant . Talsania et al., "Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice," Endocrinology 146(9):3748-56 ( Sep. 2005). cited by applicant . Tanaka et al., "Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients," Int. J. Cancer 87(5):741-749 (Sep. 2000). cited by applicant . Tong et al., "Prediction of response during interferon .alpha. 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison," Hepatology 26(6):1640-01645 (Dec. 1997). cited by applicant . Touza Rey et al., "The clinical response to interferon-.gamma. in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus," Ann. Med. Int. 17(2):86-87 (Feb. 2000). cited by applicant . Trudeau et al., "A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer," Cancer Chemother. Pharmacol. 35(6):496-500 (1995). cited by applicant . Tseng et al., "Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat," PNAS USA, 90(5):1992-1996 (1993). cited by applicant . Tsung et al., "Preparation and Stabilization of Heparin/Gelatin Complex Coacervate Microcapsules," J. Pharm. Sci. 86(5):603-7 (May 1997). cited by applicant . Unniappan et al., "Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY," Diabetologia; Clinical and Experimental Diabetes and Metabolism 49(8):1915-1923 (Jun. 27, 2006). cited by applicant . Yokes et al., "A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest," Cancer Chemother. Pharmacol. 35(4):304-312 (1995). cited by applicant . Vrabec, "Tympanic membrane perforations in the diabetic rat: a model of impaired wound healing," Otolaryngol. Head Neck Surg., 118(3 Pt. 1):304-308 (1998). cited by applicant . Wang et al., "Preferential interaction of .alpha.-tocopherol with phosphatidylcholines in mixed aqueous dispersions of phosphatidylcholine and phosphatidylethanolamine," Eur. J. Biochem. 267(21):6362-6368 (2000). cited by applicant . Wang et al., "Ripple phases induced by .alpha.-tocopherol in saturated diacylphosphatidylcholines," Archives of Biochem. & Biophys. 377(2):304-314 (2000). cited by applicant . Wang et al., "The distribution of .alpha.-tocopherol in mixed aqueous dispersions of phosphatidylcholine and phosphattidylethanolamine," Biochimica et Biophysica Acta-Biomembranes 1509(1-2):361-372 (2000). cited by applicant . Wang et al, "Parenteral formulations of proteins and peptides: stability and stabilizers," J. Parenter. Sci. Technol. 42(2S):S4-S26 (1988). cited by applicant . Weinstock-Guttman et al., "What is new in the treatment of multiple sclerosis?" Drugs 59(3):401-410 (Mar. 2000). cited by applicant . Weissmann et al., "The interferon genes," Prog. Nucleic Acid Res. Mol. Biol. 33:251-300 (1986). cited by applicant . Wright et al., "Preliminary experience with .alpha.-2b-interferon therapy of viral hepatitis in liver allograft recipients," Transplantation 53(1):121-123 (Jan. 1992). cited by applicant . Young et al., "Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)," Diabetes, 48(5):1026-1034 (1999). cited by applicant . Younossi et al., "The role of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with .alpha. interferons, in the treatment of chronic hepatitis C," Semin. Liver Dis. 19(Supp. 1):95-102 (1999). cited by applicant . Yu et al., "Preparation, characterization, and in vivo evaluation of an oil suspension of a bovine growth hormone releasing factor analog," J. Pharm. Sci. 85(4):396-401 (1996). cited by applicant . Zeidner et al., "Treatment of FeLV-induced immunodeficiency syndrome (feLV-FAIDS) with controlled release capsular implantation of 2',3'-dideoxycytidine," Antivir. Res. 11(3):147-0160 (Apr. 1989). cited by applicant . Zein, "Interferons in the management of viral hepatitis," Cytokines Cell Mol. Ther. 4(4):229-241 (Dec. 1998). cited by applicant . Zeuzem et al., "Peginterferon Alfa-2a in Patients with Chronic Hepatitis C," New Engl J. Med. 343(23):1666-1672 (2000). cited by applicant . Zeuzem et al., "Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon .alpha. on viral turnover," Hepatology 28(1):245-252 (Jul. 1998). cited by applicant . Zhang et al., "Report on Large Dosage Interferon to Treat 30 Cases of Viral Encephalitis," J. Clinical Pediatrics 14(2):83-84 (1996). cited by applicant . Zhang et al, "A new strategy for enhancing the stability of lyophilized protein: the effect of the reconstitution medium on keratinocyte growth factor," Pharm. Res. 12(10):1447-1452 (1995). cited by applicant . Zheng et al. "Therapeutic Effect of Interferon Varied Dose in Treating Virus Encephalitis," Beijing Med. J. 13(2):80-81 (1998). cited by applicant . Ziesche et al., "A preliminary study of long-term treatment with interferon .gamma.-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis," New Engl. J. Med. 341(17):1264-1269 (Oct. 1999). cited by applicant . Sanofi-Aventis U.S. LLC, Prescribing Information for Adlyxin.RTM. (Lixisenatide) Injection, for Subcutaneous Use, rev. Jul. 2016, 31 pages. cited by applicant . Amylin Pharmaceuticals, Inc., Prescribing Information for Byetta.RTM. (Exenatide) Injection, rev. Oct. 2009, 34 pages. cited by applicant . Astrazeneca Pharmaceuticals LP, Prescribing Information for Bydureon.RTM. (Exenatide Extended-Release for Injectable Suspension), rev. Mar. 2015, 60 pages. cited by applicant . Novo Nordisk A/S, Prescribing Information for Victoza.RTM. (Liraglut de [rDNA Origin] Injection), Solution for Subcutaneous Use, v. 1, Jan. 2010, 23 pages. cited by applicant . Glaxosmithkline LLC, Prescribing Information for Tanzeum.RTM. (Albiglutide) for Injection, for Subcutaneous Use, rev. Jun. 2014, 55 pages. cited by applicant . Eli Lilly & Company, Prescribing Information for Trulicity.RTM. (Dulaglutide) Injection, for Subcutaneous Use, rev. Mar. 2015, 19 pages. cited by applicant . Glumetza Brochure 2009, 13 Pages. cited by applicant . Erowid,"Introduction to the Federal Controlled Substance Analog Act" 2001, 4 pages. cited by applicant . Li et al. "Glucagon-Like Peptide-I Receptor Agonists Versus Insulin Glargine for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" in Current Therapeutic Research, vol. 71, No. 4, Aug. 2010. cited by applicant . Palmeri et al., "5-Fluorouracil and recombinant .alpha.-interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study," J. Chemotherapy 2(5):327330 (Oct. 1990). cited by applicant . Akers, et al., "Formulation Design and Development of Parenteral Suspensions," Journal of Parenteral Science & Technology, 41(3): 88-96 (1987). cited by applicant . Alonso, et al., "Determinants of Release Rate of Tetanus Vaccine from Polyester Microspheres," Pharmaceutical Research, 10(7):945-953 (1993). cited by applicant . Beck, et al., "Poly(dl-lactide-co-glycolide)/norethisterone microcapsules: An injectable biodegradable contraceptive," Biology of Reproduction, 28(1): 186-195 (1983). cited by applicant . Bodmeier and McGinity, "Solvent selection in the preparation of poly(dl-lactide) microspheres prepared by the solvent evaporation method," International Journal of Pharmaceutics, 43(1-2): 179-186 (Apr. 1988). cited by applicant . Cha and Pitt, "A one-week subdermal delivery system for I-methadone based on biodegradable microcapsules," Journal of Controlled Release, 7: 69-78 (1988). cited by applicant . Cha and Pitt, "The acceleration of degradation-controlled drug delivery from polyester microspheres," Journal of Controlled Release, 8: 259-265 (1989). cited by applicant . Cohen, et al., "Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres," Pharmaceutical Research, 8(6): 713-720 (1991). cited by applicant . Conti, et al., "Use of polylactic acid for the preparation of microparticulate drug delivery systems," Journal of Microencapsulation, 9(2): 153-166 (1992). cited by applicant . Hodgman, et al., Eds., Handbook of Chemistry and Physics, 35th Edition, 1024-1025 (1953). cited by applicant . Jalil and Nixon, "Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: Problems associated with preparative techniques and release properties," Journal of Microencapsulation, 7(3): 297-325 (Jul.-Sep. 1990). cited by applicant . Lee and Timasheff, "The stabilization of proteins by sucrose," J. Biological Chem., 256(14): 7193-7201 (Jul. 1981). cited by applicant . Li, et al., "Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microspheres prepared by solvent extraction/evaporation method," Journal of Controlled Release, 37: 199-214 (1995). cited by applicant . Maa and Hsu, "Liquid-liquid emulsification by static mixers for use in microencapsulation," Journal of Microencapsulation, 13(4): 419-433 (Jul.-Aug. 1996). cited by applicant . Maulding, et al., "Biodegradable microcapsules: Acceleration of polymeric excipient hydrolytic rate by incorporation of a basic medicament," Journal of Controlled Release, 3: 103-117 (1986). cited by applicant . Mehta, et al.,"Peptide containing microspheres from low molecular weight and hydrophilic poly(d,l-lactide-co-glycolide)," Journal of Controlled Release, 41: 249-257 (1996). cited by applicant . Sah, et al., "A novel method of preparing PLGA microcapsules utilizing methylethyl ketone," Pharmaceutical Research, 13(3): 360-367 (1996). cited by applicant . Sato, et al., "Porous biodegradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques," Pharmaceutical Research, 5(1): 21-30 (1988). cited by applicant . Szayna, et al., "Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats," Endocrinology, 141(6): 1936-1941 (2000). cited by applicant . Thomasin, et al., "A contribution to overcoming the problem of residual solvents in biodegradable microspheres prepared by coacervation," Eur. J. Pharm. Biopharm., 42(1): 16-24 (1996). cited by applicant . Van Santbrink and Fauser, "Urinary follicle-stimulating hormone for normogonadotropic colomiphene-resistant anovulatory infertility: Prospective, randomized comparison between low dose step-up and step-down dose regimens," J. Clin. Endocrin. Metab., 82(11): 3597-3602 (1997). cited by applicant . Tracy et al., "Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheresin vivo and in vitro." Biomaterials. 20(11:): 1057-1062 (1999). cited by applicant . Ertl et al., "Poly (DL-lactide-co-glycolide) microspheres as carriers for peptide vaccines," Vaccine 14(9):879-885.(1996). cited by applicant . Thompson et al., "Biodegradable microspheres as a delivery system for rismorelin porcine, a porcine-growth-hormone-releasing hormone," Journal of Controlled Release 43(1):9-22 (1997). cited by applicant.

Primary Examiner: Simmons; Ian
Assistant Examiner: Johnson; Karra S
Attorney, Agent or Firm: Moriarty; Gordon R. Trinque; Brian C. Lathrop Gage LLP

Images